Court of Chancery of Delaware October 30, 2019, 2019-0159-MTZ (Fortis Advisors LLC v. Allergan W.C. Holding Inc.)

Also known as

United States · · · 30-10-2019

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

FORTIS ADVISORS LLC, in its )

capacity as the Shareholders’ )

Representative for the former )

stockholders of Oculeve, Inc., )

)

Plaintiff, )

)

v. ) C.A. No. 2019-0159-MTZ

)

ALLERGAN W.C. HOLDING INC., )

)

Defendant. )

MEMORANDUM OPINION

Date Submitted: July 9, 2019

Date Decided: October 30, 2019

Bradley R. Aronstam, Roger S. Stronach, ROSS ARONSTAM & MORITZ LLP,

Wilmington, Delaware; Martin S. Schenker, Matthew D. Caplan, Kristine A.

Forderer, COOLEY LLP, San Francisco, California; Attorneys for Plaintiff Fortis

Advisors LLC

Michael A. Barlow, Daniel J. McBride, ABRAMS & BAYLISS LLP, Wilmington,

Delaware; David W. Haller, COVINGTON & BURLING LLP, New York, New

York; Attorneys for Defendant Allergan W.C. Holding Inc.

ZURN, Vice Chancellor.

The parties to a merger dispute the seller’s entitlement to post-closing

milestone payment consideration. For the seller to earn the milestone payment, the

new company had to achieve a specifically defined enhanced treatment authorization

from the Federal Drug Administration. After the Federal Drug Administration gave

its authorization, the company declined to pay the seller the milestone payment.

The seller stockholders’ representative asserts the buyer breached the merger

agreement by refusing to pay the milestone payment and by failing to exercise

commercially reasonable efforts in pursuit of the authorization. The buyer moved

to dismiss, contending the enhanced treatment authorization did not trigger the

milestone payment, and that the buyer failed to allege sufficient facts in support of

its commercially reasonable efforts claim. This decision concludes that the seller

adequately alleged a breach of contract claim based on the plain meaning of the

contract and the authorization, and that the seller alleged sufficient facts to support

its commercially reasonable efforts claim. Accordingly, I deny the buyer’s motion

to dismiss.

I.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.